Cervical cancer: Screening and prevention

Asian Pacific Journal of Cancer Prevention

Volumn 7, Issue 4, 2006, Pages 683-686

  Behtash, Nadereh ^a   Mehrdad, Nili ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cervical cancer; Prevention; Screening; Vaccination

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; PAPILLOMA VIRUS VACCINE; UNCLASSIFIED DRUG;

FEMALE; HUMAN; MASS SCREENING; METHODOLOGY; REVIEW; RISK FACTOR; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 33947547473     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. Baker JJ. (2002). Conventional and liquid based cervicovaginal cytology. A comparison study with clinical and histologic follow up. Diagnost Cytopath, 27, 185-8.
2. Behtash N, Mousavi A, Mohit M, et al. (2003) Simple hysterectomy in the presence of invasive cervical cancer in Iran. Int J Gynecol Cancer, 13, 177-81.
3. Dietrich AJ,Torbin JN, Cassells A, et al. (2006). Telephone care management to improve cancer screening among low- income women - a randomized controlled trial. Ann Intern Med, 144, 563-71.
4. Ghaemmaghami F, Behtash N,Modares Gilani M, et al. (2004). Visual inspection with acetic acid as a feasible screening test for cervical neoplasia in Iran. Int J Gynaecol Cancer, 14, 465-9.
5. Giovanni N, Erica M, Eduard EV, et al. (2003). Thin prep versus conventional pap smear in the cytologic follow up of women with the equivocal cervical smears. Cancer, 99, 342-5.
6. Hamkar R, Azad TM, Mahmoodhi M, et al. (2002). Prevalence of HPV in Mazandaran province, Iran. East Mediterr Health, 8, 805-11.
7. Harper DM, Franco EL,Wheeler C, et al. (2004). Sustained efficacy up to 4.5 years of a bivalent virus-like particle vaccine against HPV16 and 18: follow up from a randomized control trial. Lancet, 367, 1247-55.
8. Haverkos HW (2005). Multifactorial etiology of cervical cancer, a hypothesis. Med Gen Med, 7, 57.
9. Nuovo J, Melnikow J, Howell LP (2001) New tests for cervical cancer screening. Am Fam Physician, 64, 780-6.
10. Kulasingam SL, Myers ER, Lawson HW, et al. (2006). Costeffectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol, 107, 321-8.
11. Lorincz AT (2003). Screening for cervical cancer:new alternatives and research. Salud Publica Mex, 45 Suppl 3, S376-87.
12. Mortazavi S, Zali M, Raoufi M et al. (2002). The prevalence of HPV in cervical cancer in Iran. Asian Pac J Cancer Prev, 3, 69-72.
13. Omeara AT (2002). Present standards for cervical cancer screening Current Opinion Oncol, 14, 505-11.
14. Rydstorm C, Tornberg S (2006). Cervical cancer incidence and mortality in the best and worst of worlds. Scand J Public Health, 34, 295-303.
15. Sangwa-Lugoma G, Mahmud S, Nasr SH, et al. (2006). Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer, 119, 1389-95.
16. Walmer D, Merisier D, Littman E, et al. (2004). Portable colposcopy in low-resource settings. J Acquir Immune Defic Syn, 37(suppl 3), S167-70.